Capecitabine/Cyclophosphamide - SanofiAlternative Names: Cyclophosphamide/Capecitabine - Sanofi
Latest Information Update: 24 Feb 2016
At a glance
- Originator Sanofi
- Class Antineoplastics; Carbamates; Cyclophosphamides; Myeloablative agonists; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Alkylating agents; Immunomodulators; Thymidylate synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer
Most Recent Events
- 05 Feb 2016 Preclinical trials in Breast cancer in France (PO)